Sponsor: National Cancer Institute
Sponsor Study ID:
Study Title: Refining Tamoxifen Dose for Premenopausal Breast Cancer Prevention (RENAISSANCE): A Phase II Single Arm Trial
CTO #: 103965
NCT Number: NCT06184750
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Breast
Study Objectives: The primary objective of this study is to evaluate whether the overall proportion of premenopausal tamoxifen responders (defined by absolute dense area reduction on mammogram of >10%) can be increased through a strategy of within-individual dose escalation among non-responders from 5 mg per day to 10 mg per day.